The therapeutic potential of tacrine

Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 54)


Tacrine, a non-competitive inhibitor of acetylcholine esterase, has been approved for the treatment of patients with mild to moderate Alzheimer’s disease in 1995. The available evidence suggests that in a substantial proportion of patients tacrine has the potential to improve cognitive functions, to ameliorate behavioural problems, and to delay the time to significant clinical endpoints. Thus, tacrine meets realistic expectations from symptomatic treatment. The major safety concern about tacrine is the probability of liver enzyme elevations and the high frequency of adverse events, particularly gastrointestinal. Findings are presented from an open-label multicentre study showing that tacrine is a safe and manageable compound in private practice.


Liver Enzyme Elevation Nursing Home Admission Major Safety Concern Aberrant Motor Behaviour Progressive Deterioration Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, rev. American Psychiatric Association, WashingtonGoogle Scholar
  2. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308–3214PubMedCrossRefGoogle Scholar
  3. De Jong R, Ostersund OW, Roy GW (1989) Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 11: 545–554Google Scholar
  4. Erzigkeit H (1989) SKT. Ein Kurztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen. Beltz, WeinheimGoogle Scholar
  5. Gracon SI (1996) Evaluation of tacrine hydrochloride (Cognex®) in two parallel-group studies. Acta Neurol Scand [Suppl] 165: 114–122CrossRefGoogle Scholar
  6. Gutzmann H, Hadler D, Erzigkeit H (1997) Long-term treatment of Alzheimer’s disease with idebenone. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer’s disease: biology, diagnosis and therapeutics. Wiley, New York, pp 688–705Google Scholar
  7. Kaufer DI, Cummings JL, Christine D (1996) Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol 9: 1–6PubMedGoogle Scholar
  8. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 271(13): 985–991PubMedCrossRefGoogle Scholar
  9. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S (1996) Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 47: 166–177PubMedCrossRefGoogle Scholar
  10. McKhann G, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939–944PubMedCrossRefGoogle Scholar
  11. Mohs RC, Cohen L (1988) Alzheimer’s Disease Assessment Scale (ADAS). Psychopharmacol Bull 24(4): 627–628PubMedGoogle Scholar
  12. Watkins PB, Zimmerman HJ, Knapp MG, Gracon SI, Lewis KW (1994) Hepatotoxic effecs of tacrine administration in patients with Alzheimer’s disease. JAMA 271(13): 992–998PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • A. Kurz
    • 1
  1. 1.Department of PsychiatryTechnical UniversityMünchenFederal Republic of Germany

Personalised recommendations